An Open-Label, Phase 1 Clinical Study to Evaluate the Safety &

Clinical Trial Summary

This is an open-label, Phase 1 single-center study in approximately 40 subjects who have 1 eye with intermediate AMD, including a high-risk drusen without geographic atrophy (GA) subgroup and a noncentral GA subgroup. Eligible subjects will receive 40 mg of elamipretide administered as a once daily 1.0 mL subcutaneous injection for 12 weeks.

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05984927` - NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration	Phase 1/Phase 2
Active, not recruiting	`NCT05536297` - Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy	Phase 3
Recruiting	`NCT04101604` - Biomarkers of Common Eye Diseases
Completed	`NCT04005352` - Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)	Phase 3
Withdrawn	`NCT02873351` - A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration	Phase 2
Active, not recruiting	`NCT02802657` - Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration	Phase 4
Not yet recruiting	`NCT02864472` - Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose	Phase 4
Recruiting	`NCT01521065` - An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration	Phase 2
Completed	`NCT02035722` - Intravitreal Injections-related Anxiety	Phase 2/Phase 3
Completed	`NCT01445548` - Sirolimus for Advanced Age-Related Macular Degeneration	Phase 1/Phase 2
Completed	`NCT01175395` - 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)	Phase 1/Phase 2
Recruiting	`NCT01048476` - Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration	Phase 1/Phase 2
Active, not recruiting	`NCT01174407` - Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration	N/A
Terminated	`NCT00712491` - Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration	Phase 1/Phase 2
Completed	`NCT00345176` - Age-Related Eye Disease Study 2 (AREDS2)	Phase 3
Completed	`NCT02140151` - Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration	Phase 1/Phase 2
Completed	`NCT02555306` - A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration	Phase 1/Phase 2
Recruiting	`NCT04796545` - Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration	N/A
Completed	`NCT03166202` - Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a Simulator
Completed	`NCT01397409` - Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)	Phase 2

NCT number	NCT02848313
Study type	Interventional
Source	Stealth BioTherapeutics Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	October 28, 2016
Completion date	April 10, 2018

An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms